Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome
NCT06953661Recruiting
- Sponsor
- Stanford University
- Start
- Oct 2025
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine in postural orthostatic tachycardia syndrome (POTS) (2 arms), sponsored by Stanford University. Primary endpoint: Composite Autonomic Symptom Score 31. Started Oct 2025; status: recruiting.
02
Drugs
ropivacaine
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT06953661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953661.